Equities

Medcamp SA

MDP:WSE

Medcamp SA

Actions
Real EstateReal Estate Investment and Services
  • Price (PLN)0.56
  • Today's Change-0.01 / -1.75%
  • Shares traded622.00
  • 1 Year change-39.78%
  • Beta--
Data delayed at least 15 minutes, as of May 02 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medcamp SA, formerly T2 Investment SA, is a Poland-based company engaged in the real estate operations. The Company is involved in the acquisition, management, redevelopment and upgrade, as well as rental and sale of commercial properties, including office areas and warehouses. In addition, the Company is involved in long-term investments in construction and real estate entities. It conducts rental and redevelopment projects, such as Poznan, Jasielska; Poznan, Komorniki; Poznan, Jasielska, Inkubator; Szamotuly, Dworcowa; among others. The Company aims to build a research and development center in Poznan, specializing in such areas as personalized medicine, genetics, genomics and bioinformatics, supported by artificial intelligence, The Company operates through subsidiaries, including T2 Inkubator Sp z o o, T2 Szamotuly Sp z o o, Polskie Centrum Badan i Rozwoju Sp z o o, among others. The majority shareholder of the Company is Moonrock Enterprise SA.

  • Revenue in PLN (TTM)0.00
  • Net income in PLN-2.05m
  • Incorporated2007
  • Employees0.00
  • Location
    Medcamp SAul. Jeleniogorska 16 C/3POZNAN 60-179PolandPOL
  • Phone+48 616648000
  • Fax+48 616648029
  • Websitehttps://medcampsa.pl/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
New Tech Capital SA-100.00bn-100.00bn9.66m6.00--0.9823----------0.68-----------13.50---20.33--97.78---331.510.0471--0.0794---100.00---2,446.60------
Reinhold Europe AB0.00-675.50k12.60m5.00---------0.0047-0.00470.00-0.03760.00-------10.13-75.08---460.92----------0.2277--------87.60------
Clean&carbon Energy SA148.00k-377.00k13.57m13.00--1.28--91.72-0.011-0.0110.00430.31010.0102--3.36---2.59-19.76-3.49-21.21-135.14-6.97-254.73-9,290.250.0177-4.890.1177-----29.2799.83------
Medcamp SA0.00-2.05m14.64m0.00--1.65-----0.0784-0.07840.000.33980.00-------18.64-40.15-20.26-43.01-------351,167.609.97-0.16540.0325------62.96------
Elkop SE18.96m6.39m22.47m18.003.520.23593.461.190.13870.13870.41182.070.1377--13.931,053,445.004.644.814.754.8835.7245.4033.6945.04--5.290.2314--17.2732.79-1.6530.955.49--
Alta SA572.00k2.47m32.07m3.0012.910.165712.8456.060.16270.16270.037412.680.003--1.32190,666.701.272.131.282.1896.3395.85431.99462.71----0.00001---21.18-18.24-46.981.07-13.65--
CPD SA-14.73m51.98m35.69m39.001.0662.031.51--3.753.75-2.190.0642-0.1575------55.585.12109.616.75--65.64--110.16----0.00---96.08-48.13-61.7339.75----
CZERWONA TOREBKA SA15.45m-14.42m50.27m441.00--0.3887--3.25-0.1922-0.19220.20591.720.06390.190523.02---5.96-5.20-7.01-6.202.93-0.3293-93.35-174.771.00-2.470.1837---68.86-21.62-178.88------
Data as of May 02 2024. Currency figures normalised to Medcamp SA's reporting currency: Polish New Zloty PLN
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.